Correction Notice: Inaccuracy in Figure 1B of the Original Investigation

Overview

This correction notice addresses an error in Figure 1B of the original investigation on dual immune checkpoint inhibition in rectal cancer. The bar colors representing neoadjuvant scores above 16 were incorrectly depicted and have been amended.

Background

Accurate representation of data in clinical research is crucial for proper interpretation and application in practice.

Data Highlights

No numerical or trial data is presented in this correction notice.

Key Findings

• The bar colors in Figure 1B were corrected from green to red for neoadjuvant scores above 16.
• The original investigation was published on August 22, 2025.

Clinical Implications

Healthcare professionals should ensure they are referencing the corrected figures in clinical studies to avoid misinterpretation. Continuous vigilance in reviewing published data is necessary to maintain clinical accuracy.

Conclusion

The correction of Figure 1B is a reminder of the importance of accuracy in clinical research publications. Proper representation of data is vital for informed clinical practice.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. ASCO Publications — Erratum: Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
3. ASCO Publications — Quantification of immune response after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
4. ASCO Publications — Reply to: “Is Dual-Checkpoint Blockade Beneficial Beyond Prolonging Chemoradiotherapy-to-Surgery Interval in Rectal Cancer?” and “Dual Immunotherapy in the Neoadjuvant Interval for Locally Advanced Rectal Cancer: A New Hope?”
5. Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer
6. Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial - PubMed
7. Immune checkpoint inhibitors with neoadjuvant chemoradiotherapy in proficient MMR rectal cancer: systematic review and meta-analysis | Radiation Oncology | Springer Nature Link